Superior Efficacy and Safety of the "Bridge Technique" Self-Traction in Endoscopic Submucosal Dissection for Semi-Circumferential Gastric Cardia Neoplasms: A Randomized Controlled Trial

Therapeutic efficacy of the "Bridge Technique" self-traction method for Endoscopic Submucosal Dissection (ESD) of cardiac neoplasm involving more than half the circumference

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600119809

Enrollment

Unknown

Registered

2026-03-04

Start date

2020-07-01

Completion date

Unknown

Last updated

2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cardia Neoplasms

Interventions

Conventional ESD(CESD) :The procedure was regularly performed with a single-channel endoscope (GIF-Q260J

Olympus Optical, Tokyo, Japan) with a transparent cap attached. The conventional ESD techniques were previously detailed. Briefly, following the placement of circumferential marking dots outside the l

Anrei Medical Co., Ltd., China). Hemostasis during the procedure was achieved endoscopically using either the knife tip itself or hemostatic forceps.

The "Bridge Technique" self-traction ESD (BT-ESD) :The procedure was regularly performed with a single-channel endoscope (GIF-Q260J

Olympus Optical, Tokyo, Japan) with a transparent cap attached.The mucosal incision around the lesion is performed in the same manner as in conventional ESD. During submucosal dissection in the forwar

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 18–80 years. 2. Pathologically confirmed via endoscopic biopsy as adenoma or early adenocarcinoma (including high-grade intraepithelial neoplasia) of the gastric cardia (defined as within 2 cm distal to the gastroesophageal junction). 3. Lesions meeting absolute or extended ESD indications per the Japanese Gastric Cancer Treatment Guidelines: (1) Non-ulcerative mucosal-layer intestinal-type adenocarcinoma (cT1a stage, any size); (2) Ulcerative mucosal-layer intestinal-type adenocarcinoma =50% (semi-circumferential infiltration); (2) Maximum diameter >=3cm. 5. Preoperative endoscopic ultrasound (EUS) and magnifying endoscopy (ME) confirm infiltration depth meets ESD treatment criteria. 6. Preoperative contrast-enhanced chest and abdominal CT excludes lymph node metastasis and distant metastasis. 7. Written informed consent has been obtained.

Exclusion criteria

Exclusion criteria: 1.Evidence of lymph node or distant metastasis on imaging studies. 2.Severe systemic diseases precluding safe anesthesia or endoscopic procedures (e.g., New York Heart Association Class III/IV heart failure, severe respiratory insufficiency). 3.Uncorrected coagulopathy. 4.History of prior gastric surgery involving the cardia region. 5)Pregnancy or lactation.

Design outcomes

Primary

Measure	Time frame
Complete resection rate;Delayed bleeding;	—

Secondary

Measure	Time frame
procedure duration;resection speed;Intraprocedural bleeding frequency;Intraoperative injection volume(ml); Perforation;infection;Postprocedural stricture;	—

Countries

China

Contacts

Public ContactLinyun Xue

The First Hospital of Putian City

linyunxue83@163.com+86 188 5090 9922

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 31, 2026